Celldex Therapeutics (CLDX) Stock Analysis & AI Equity Report
Celldex Therapeutics (CLDX) overview
Celldex Therapeutics (CLDX) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 1.5m and operating profit of USD -287m; the year-end share price was 27.16 USD and market capitalisation was USD 1,807m. Celldex Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Celldex Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Celldex Therapeutics
Celldex Therapeutics is a biopharmaceutical company focused on mast cell biology and the development of therapeutic antibodies for inflammatory, allergic, autoimmune, and other serious diseases. Its investigational pipeline includes monoclonal and bispecific antibody candidates, including programs targeting mast cell driven diseases and inflammatory pathways. The company conducts research and clinical development of potential therapies for patients whose conditions have inadequate treatment options.
Generate the Celldex Therapeutics report
Celldex Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Celldex Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Celldex Therapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.